Skip to main content
SpringerLink
Log in

Medikamente zur Behandlung von Schlafstörungen

  • Chapter
  • First Online:
Kompendium der Psychiatrischen Pharmakotherapie

  • 8189 Accesses

Zusammenfassung

Indikationen, Wirkungsweise, Nebenwirkungen und Risiken, Kontraindikationen und Interaktionen werden für die Medikamente gegen Schlafstörungen beschrieben. Diese werden entsprechend den DSM-5- und ICD11-Kriterien neu geordnet. Die Strukturen innerhalb der einzelnen Diagnosen sind geblieben.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Allen RP, Picchietti DL, Auerbach M et al; International Restless Legs Syndrome Study Group (IRLSSG) (2018) Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report. Sleep Med 41:27–44

    Article  Google Scholar 

  • Avni T, Reich S, Lev N, Gafter-Gvili A (2019) Iron supplementation for restless legs syndrome – a systematic review and meta-analysis. Eur J Intern Med 63:34–41

    Article  CAS  Google Scholar 

  • Baladi MG, Forster MJ, Gatch MB et al (2018) Characterization of the neurochemical and behavioral effects of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 366:367–376

    Article  CAS  Google Scholar 

  • Borovac JA (2016) Side effects of a dopamine agonist therapy for Parkinson’s disease: a mini-review of clinical pharmacology. Yale J Biol Med 89:37–47

    CAS  PubMed  PubMed Central  Google Scholar 

  • Dauvilliers Y, Verbraecken J, Partinen M et al; HAROSA II study group (2020) Pitolisant for daytime sleepiness in obstructive sleep apnea patients refusing CPAP: a randomized trial. Am J Respir Crit Care Med 201:1135–1145

    Article  Google Scholar 

  • Dresler M, Spoormaker VI, Beitinger P et al (2014) Neuroscience-driven discovery and development of sleep therapeutics. Pharmacol Ther 141:300–334

    Article  CAS  Google Scholar 

  • Emsellem HA, Thorpy MJ, Lammers GJ et al (2019) Measures of functional outcomes, work productivity, and quality of lifefrom a randomized phase 3 study of solriamfetol in participants with narcolepsy. Sleep Med 67:128

    Article  Google Scholar 

  • Garcia-Borreguero D, Cano-Pumarega I (2017) New concepts in the management of restless legs syndrome. BMJ 356:j104

    Article  Google Scholar 

  • Garcia-Borreguero D, Silber MH, Winkelman JW et al (2016) Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Med 21:1–11

    Article  Google Scholar 

  • Huddart R, Clarke M, Altman RB, Klein TE (2018) PharmGKB summary: oxycodone pathway, pharmacokinetics. Pharmacogenet Genomics 28(10):230–237

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Iftikhar IH, Alghothani L, Trotti LM (2017) Gabapentin enacarbil, pregabalin and rotigotine are equally effective in restless legs syndrome: a comparative meta-analysis. Eur J Neurol 24(12):1446–1456

    Article  CAS  Google Scholar 

  • Jacobson LH, Chen S, Mir S, Hoyer D (2016) Orexin OX2 receptor antagonists as sleep aids. In: Lawrence A, de Lecea L (Hrsg) Behavioral neuroscience of orexin/hypocretin. Current topics in behavioral neurosciences, Bd. 33. Springer, Berlin Heidelberg New York

    Chapter  Google Scholar 

  • Keks NA, Hope J, Keogh S (2017) Suvorexant: scientifically interesting, utility uncertain. Australas Psychiatry 25:622–624

    Article  Google Scholar 

  • Klepitskaya O, Lui Y, Sharma S et al (2018) Deep brain stimulation improves restless legs syndrome in patients with Parkinson disease. Neurology 91(11):e1013–e1021

    Article  Google Scholar 

  • Malhotra A, Shapiro C, Pepin JL et al (2020) Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea. Sleep 43(2):zsz220

    Article  Google Scholar 

  • Mayer G (2014) Narkolepsie. Nervenarzt 85:26–34

    Article  CAS  Google Scholar 

  • Mittal SO, Machado D, Richardson D et al (2018) Botulinum toxin in eestless legs syndrome – a randomized double-blind placebo-controlled crossover study. Toxins 10(10):E401

    Article  Google Scholar 

  • Nissen C, Frase L, Hajak G, Wetter TC (2014) Hypnotika – Stand der Forschung. Nervenarzt 85:67–76

    Article  CAS  Google Scholar 

  • O’Reardon JP, Stunkard AJ, Allison KC (2004) Clinical trial of sertraline in the treatment of night eating syndrome. Int J Eat Disord 35:16–26

    Article  Google Scholar 

  • Pollmächer T, Wetter TC, Happe S et al (2014) Schlafmedizinische Differenzialdiagnostik in Psychiatrie und Psychotherapie. Nervenarzt 85:57–66

    Article  Google Scholar 

  • Riemann D, Baglioni C, Feige B, Spiegelhalder K (2014) Insomnien – Stand der Forschung. Nervenarzt 85:43–49

    Article  CAS  Google Scholar 

  • Riemann D, Baglioni C, Basetti C et al (2017a) European guideline for the diagnosis and treatment of insomnia. J Sleep Res 26:675–600

    Article  Google Scholar 

  • Riemann D, Baum E, Cohrs S et al (2017b) S3-Leitlinie Nicht erholsamer Schlaf/Schlafstörungen. Kapitel „Isomnie bei Erwachsenen“. Somnologie 21:2–44

    Article  Google Scholar 

  • Saper CB, Fuller PM (2017) Wake-sleep circuitry: an overview. Curr Opin Neurobiol 44:186–192

    Article  CAS  Google Scholar 

  • Schweitzer P, Strohl KP, Malhotra A et al (2018) 0622 Solriamfetol (JZP-110) in the treatment of excessive sleepiness in narcolepsy and obstructive sleep apnea: maintenance of wakefulness test results across the day. Sleep 41:A231–A231

    Article  Google Scholar 

  • TONES 3 Study Investigators, Schweitzer PK, Rosenberg R, Zammit GK et al (2019) Solriamfetol for excessive sleepiness in obstructive sleep apnea (TONES 3). A randomized controlled trial. Am J Respir Crit Care Med 199:1421–1431

    Article  Google Scholar 

  • Scientific and Medical Advisory Board, Restless Legs Syndrome Foundation, Silber MH, Becker PM, Buchfuhrer MJ et al (2018) The appropriate use of opioids in the treatment of refractory restless legs syndrome. Mayo Clin Proc 93(1):59–67

    Article  Google Scholar 

  • Stallman HM, Kohler M, White J (2018) Medication induced sleepwalking: a systematic review. Sleep Med Rev 37:105–113

    Article  Google Scholar 

  • Steiger A (2018) Tasimelteon reentrains sleep period in a patient with phase delay syndrome. J Sleep Res 27:P062, 120

    Google Scholar 

  • Steiger A, Pawlowski M, Kimura M (2015) Sleep electroencephalography as a biomarker in depression. Chronophysiol Ther 5:15–25

    Article  Google Scholar 

  • Suzuki M, Yukitake H, Ishikawa T, Kimura H (2018) An orexin 2 receptor-selective agonist Tak-925 ameliorates narcolepsy-like symptoms in orexin/ataxin-3 mice. Sleep 41:A1–A1

    Article  Google Scholar 

  • Trenkwalder C, Benes H, Grote L et al, for the RELOXYN Study Group (2013) Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol 12:1141–1150

    Article  Google Scholar 

  • Trenkwalder C, Winkelmann J, Inoue Y, Paulus W (2015) Restless legs syndrome – current therapies and management of augmentation. Nat Rev Neurol 11(8):434–445

    Article  Google Scholar 

  • Yang X, Yang B, Ming M et al (2019) Efficacy and tolerability of intravenous iron for patients with restless legs syndrome: evidence from randomized trials and observational studies. Sleep Med 61:110–117

    Article  Google Scholar 

  • Yukitake H, Fujimoto T, Ishikawa T et al (2019) TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice. Pharmacol Biochem Behav 187:172794

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Kaiserslautern/München, Deutschland

    Prof. Dr. med. Axel Steiger

  2. Cham, Deutschland

    Prof. Dr. med. Frank Weber

  3. Mainz, Deutschland

    Otto Benkert

Authors
  1. Prof. Dr. med. Axel Steiger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Frank Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Otto Benkert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Otto Benkert .

Editor information

Editors and Affiliations

  1. ehemals Universitäts-Klinikum Mainz, Mainz, Germany

    Otto Benkert

  2. Klinik für Psychiatrie und Psychotherapie, ehemals Universitäts-Klinikum München Campus Innenstadt, München, Germany

    Hanns Hippius

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Steiger, A., Weber, F., Benkert, O. (2021). Medikamente zur Behandlung von Schlafstörungen. In: Benkert, O., Hippius, H. (eds) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-61753-3_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-61753-3_5

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-61752-6

  • Online ISBN: 978-3-662-61753-3

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation